LASA - Lasa Supergeneri
📢 Recent Corporate Announcements
Lasa Supergenerics has reported a severe operational crisis following a major fire at its primary 'Mother Unit' in Ratnagiri. The company recognized exceptional losses totaling approximately ₹20.57 crore, including ₹12.74 crore in inventories and ₹7.00 crore in property and equipment, none of which were covered by insurance. Consequently, all production activities have ceased, and the company is struggling with statutory clearances to restart. Auditors have raised significant concerns regarding the company's ability to continue as a going concern.
- Exceptional loss of ₹1,273.62 Lakhs recognized for inventories destroyed in a fire incident.
- Provisional loss of ₹700 Lakhs recorded for damaged Property, Plant, and Equipment (PPE).
- Total halt of manufacturing operations at the central C-4 unit and all dependent leased units since May 2025.
- Management confirmed that the affected assets were not covered by insurance, leading to a total financial loss.
- Auditors highlighted dormant bank accounts and fixed deposits totaling ₹39.45 Lakhs that could not be confirmed.
Lasa Supergenerics has reported a complete cessation of manufacturing activities following a major fire at its primary 'Mother Unit' in May 2025. The company recognized a significant exceptional loss of ₹2,057.47 lakhs (approximately ₹20.57 crore) covering destroyed inventory and property, which was notably uninsured. Auditors have highlighted 'going concern' risks as the company is currently unable to restart operations and is exploring alternative contract manufacturing or leasing models. Furthermore, several bank accounts and fixed deposits totaling ₹39.45 lakhs remain dormant and unconfirmed.
- Total exceptional loss of ₹2,057.47 lakhs recognized due to fire damage at the Lote Parshuram unit.
- Affected assets including inventories (₹1,273.62 lakhs) and PPE (₹700 lakhs) were not covered by insurance.
- All production processes have halted as the primary 'Mother Unit' is non-functional, impacting all subsequent units.
- Auditors raised concerns over dormant bank balances of ₹7.99 lakhs and fixed deposits of ₹31.46 lakhs.
- Management is exploring contract manufacturing or leasing options due to inability to restart own facilities.
Lasa Supergenerics Limited has reported a complete suspension of operations following a major fire at its primary 'Mother Unit' in May 2025. The company recognized a significant uninsured exceptional loss of approximately ₹20.57 crore, comprising ₹12.73 crore in inventory and ₹7 crore in property and equipment. Management has expressed an inability to restart manufacturing due to statutory and operational constraints, leading the auditor to raise concerns about the company's status as a going concern. The company is currently exploring alternative options such as contract manufacturing or leasing its facilities.
- Total exceptional loss of ₹2,057.47 Lakhs recognized due to a fire incident at the Ratnagiri factory.
- Assets affected by the fire were not covered by insurance, leading to a direct hit on the balance sheet.
- All production processes have ceased as the primary unit (C-4) was central to all company operations.
- Auditor highlighted unconfirmed dormant bank balances of ₹7.99 Lacs and fixed deposits of ₹31.46 Lacs.
- Revenue recognition for specific invoices suspended under force majeure due to destruction of goods before risk transfer.
Lasa Supergenerics reported a severe operational crisis in its Q3 FY26 results following a major fire at its primary manufacturing unit. The company recognized an exceptional loss of approximately ₹20.57 crore, which was notably uninsured, covering inventory and property damage. All production activities have ceased across all units as the 'Mother Unit' remains non-functional. Management is currently exploring contract manufacturing or leasing options as they are unable to restart own manufacturing due to statutory and operational constraints.
- Total exceptional loss of ₹2,057.47 Lakhs recognized due to an uninsured fire incident at the Lote Parshuram factory.
- Breakdown of losses includes ₹1,273.62 Lakhs in inventories and ₹700.00 Lakhs in property, plant, and equipment.
- Production at all units has completely ceased as subsequent units were dependent on the damaged 'Mother Unit'.
- Auditors raised concerns over dormant bank accounts and fixed deposits totaling ₹39.45 Lakhs for which confirmations were unavailable.
- Company is facing 'going concern' challenges and is exploring alternative business models like contract manufacturing.
Lasa Supergenerics Limited has submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended December 31, 2025. The company confirmed that it maintains an internal, non-tamperable system to track Unpublished Price Sensitive Information (UPSI) in accordance with SEBI Insider Trading regulations. For the reported quarter, the company identified 2 specific events that required logging and successfully captured both. No instances of non-compliance were observed, reflecting the company's adherence to standard corporate governance protocols.
- Achieved 100% compliance with SEBI (Prohibition of Insider Trading) Regulations for Q3 FY26.
- Successfully captured 2 required UPSI events in the Structured Digital Database during the quarter.
- Maintains a non-tamperable internal database with an 8-year record retention capability and audit trail.
- Reported zero non-compliances or pending remedial actions for the reporting period.
Lasa Supergenerics Limited has filed its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The certificate, issued by Bigshare Services Private Limited, confirms that all dematerialization requests were processed within the mandated 15-day timeframe. It verifies that security certificates received were mutilated, cancelled, and the depositories' names were updated in the register of members. This is a standard administrative filing confirming the company's adherence to regulatory norms regarding share processing.
- Compliance certificate issued for the quarter ended December 31, 2025.
- Bigshare Services Private Limited confirmed processing of all dematerialization requests.
- Security certificates were mutilated and cancelled after due verification by the depository participant.
- Register of members updated with depository names within 15 days of receipt of certificates.
Lasa Supergenerics Limited has announced the appointment of Mr. Ganesh Suresh Potdar as an Additional Director in the capacity of Executive Director, effective January 02, 2026. His tenure is set for four years, concluding on January 01, 2030, subject to shareholder approval. In addition to his board role, he will serve as the 'Occupier' for all of the company's manufacturing units. Mr. Potdar brings expertise in business operations and banking-related processes but currently holds zero shares in the company.
- Appointment of Mr. Ganesh Suresh Potdar as Executive Director effective January 02, 2026.
- The designated term for the appointment is 4 years, ending on January 01, 2030.
- Mr. Potdar will also function as the 'Occupier' for all company units, overseeing operational compliance.
- The appointee holds 0 shares in the company and has no other public directorships.
Lasa Supergenerics Limited has officially notified the stock exchanges regarding the closure of its trading window for all designated persons and their immediate relatives. This closure is effective from January 01, 2026, in anticipation of the upcoming financial results for the quarter ending December 31, 2025. The window will remain shut until 48 hours after the public declaration of the unaudited financial results. This is a standard regulatory procedure under SEBI's Prohibition of Insider Trading Regulations to ensure market integrity.
- Trading window closure begins on January 01, 2026.
- Closure is related to the unaudited financial results for the quarter ended December 31, 2025.
- Restriction applies to designated employees and their immediate relatives.
- Trading window will reopen 48 hours after the financial results are declared.
Lasa Supergenerics Limited announced the resignation of Mr. Prathmesh Chalke (DIN: 11119348) as Executive Director, effective from the closing hours of December 31, 2025. Mr. Chalke confirmed that there are no other material reasons for his resignation besides those mentioned in his resignation letter dated December 11, 2025. The company has complied with Regulation 30 of the listing regulations and SEBI Circular No. CIR/CFD/CMD/4/2015. This change in leadership may have implications for the company's strategic direction.
- Mr. Prathmesh Chalke (DIN: 11119348) has resigned as Executive Director.
- Resignation is effective from December 31, 2025.
- The resignation complies with Regulation 30 of SEBI listing regulations.
- Resignation letter dated 11th December 2025.
Financial Performance
Revenue Growth by Segment
Total income from operations grew 36.53% YoY from INR 104.34 Cr in FY24 to INR 142.45 Cr in FY25. Segment-specific growth percentages are not disclosed in the available documents.
Profitability Margins
EBITDA margin improved significantly from 2.17% in FY24 to 7.92% in FY25. However, the company remains loss-making at the net level, with a Net Loss of INR 14.71 Cr in FY25 compared to a loss of INR 21.62 Cr in FY24, representing a 31.96% reduction in losses.
EBITDA Margin
EBITDA margin stood at 7.92% (INR 11.28 Cr) in FY25, up from 2.17% (INR 2.27 Cr) in FY24. This improvement was driven by higher operational income and better cost management despite a 33.29% increase in total expenditure.
Capital Expenditure
The company undertook a debt-free capex by procuring 17-18 new reactors through internal accruals. Property, Plant and Equipment (PPE) decreased from INR 81.16 Cr in Sept 2024 to INR 39.70 Cr in Sept 2025, reflecting consolidation and potential impairments.
Credit Rating & Borrowing
Current borrowings were reduced by 63.74% from INR 20.24 Cr in Sept 2024 to INR 7.34 Cr in Sept 2025. Finance costs for H1 FY26 dropped 93.11% to INR 0.15 Cr from INR 2.11 Cr in H1 FY25, following the company's strategy to reach zero finance costs.
Operational Drivers
Raw Materials
Active Pharmaceutical Ingredients (APIs) and related chemical intermediates. Specific raw material names and their percentage of total cost are not disclosed.
Capacity Expansion
The company recently procured 17-18 new reactors to expand capacity. Manufacturing is being consolidated into a single facility at MIDC Lote Parshuram to enhance operational efficiency and mitigate risks from past disruptions.
Raw Material Costs
Total expenditure (including raw materials) was INR 136.18 Cr in FY25, representing 95.6% of operational revenue. This is a slight improvement from 97.9% in FY24.
Manufacturing Efficiency
The company is focusing on debottlenecking existing units and commissioning new reactors (expected within one quarter of procurement) to improve throughput.
Strategic Growth
Expected Growth Rate
20-25%
Growth Strategy
Growth will be driven by the launch of two new 'blockbuster' products with high market demand, debottlenecking existing manufacturing units, and the operationalization of 17-18 new reactors. The company also expects to benefit from the global shift away from Chinese API sourcing.
Products & Services
Active Pharmaceutical Ingredients (APIs) and proprietary molecules developed through process patents.
Brand Portfolio
Lasa Supergenerics.
New Products/Services
Two blockbuster products are planned for launch; production was expected to commence around August 2025 following reactor commissioning.
Market Expansion
Targeting growth in the API market driven by the slowdown in the Chinese economy and increasing global demand for diversified supply chains.
Strategic Alliances
The company previously paid job work charges to Harishree, which are expected to be eliminated post-merger to improve the bottom line.
External Factors
Industry Trends
The API industry is seeing a positive outlook for FY25 due to a slowdown in the Chinese economy, allowing Indian manufacturers like LASA to capture market share. The industry is shifting toward higher regulatory compliance and consolidated manufacturing.
Competitive Landscape
Competes in the global API market; faces competitive pressures from other generic manufacturers and potential currency fluctuations.
Competitive Moat
The company's moat is built on 100% proprietary ownership of process patents and a transition to a debt-free capital structure, which protects margins from interest rate volatility.
Macro Economic Sensitivity
Highly sensitive to geopolitical stability and climate change, which disrupt trade routes and manufacturing activities.
Consumer Behavior
Increased demand for transparency and regulatory compliance in pharmaceutical supply chains.
Geopolitical Risks
Conflicts in Eastern Europe and the Middle East are cited as primary risks to economic stability and supply chain integrity.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent global regulatory standards for API manufacturing; delays in approvals are a significant risk to commercialization.
Environmental Compliance
Consolidation of units was partly prompted by the need to better manage environmental and compliance risks following past incidents.
Taxation Policy Impact
The company reported a deferred tax expenditure of INR 4.63 Cr in FY25 compared to a deferred tax income of INR 2.62 Cr in FY24.
Legal Contingencies
The company is involved in ongoing litigation with insurance companies, tax authorities, and financial institutions. A major contingency is the lack of insurance coverage due to insurer disputes.
Risk Analysis
Key Uncertainties
The lack of insurance coverage for manufacturing facilities poses a catastrophic risk. Banking disputes also threaten working capital availability.
Geographic Concentration Risk
Manufacturing is heavily concentrated in a single facility at MIDC Lote Parshuram, Maharashtra.
Technology Obsolescence Risk
The company mitigates technology risk by investing in new reactors and proprietary process patents.
Credit & Counterparty Risk
Trade receivables stood at INR 1.59 Cr as of Sept 30, 2025, a 56.9% decrease from INR 3.69 Cr in Sept 2024, suggesting improved collection or lower sales volume.